Geode Capital Management LLC Acquires 22,059 Shares of XBiotech Inc. (NASDAQ:XBIT)

Geode Capital Management LLC raised its stake in shares of XBiotech Inc. (NASDAQ:XBIT) by 5.1% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 452,264 shares of the biopharmaceutical company’s stock after acquiring an additional 22,059 shares during the period. Geode Capital Management LLC owned approximately 1.48% of XBiotech worth $3,496,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in XBIT. Jane Street Group LLC purchased a new stake in XBiotech during the third quarter valued at approximately $86,000. MetLife Investment Management LLC bought a new position in XBiotech in the 3rd quarter worth $94,000. Rhumbline Advisers lifted its position in XBiotech by 2,568.5% during the second quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 19,341 shares in the last quarter. Barclays PLC grew its holdings in XBiotech by 247.4% during the third quarter. Barclays PLC now owns 26,343 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 18,761 shares during the period. Finally, FMR LLC grew its holdings in XBiotech by 34.4% during the third quarter. FMR LLC now owns 28,992 shares of the biopharmaceutical company’s stock valued at $224,000 after purchasing an additional 7,420 shares during the period. Institutional investors own 55.70% of the company’s stock.

XBiotech Stock Up 1.4 %

NASDAQ XBIT opened at $4.48 on Tuesday. The stock’s 50-day moving average price is $6.36 and its 200-day moving average price is $6.53. The company has a market capitalization of $136.56 million, a P/E ratio of -4.15 and a beta of 1.44. XBiotech Inc. has a 52 week low of $3.51 and a 52 week high of $9.96.

XBiotech Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.